ERBB2 and neoplasm: Some studies proposed that the promotion of the active targeted nanoparticle’s targeting efficiency at the tumor site was not totally ideal, for example, folate receptor modified liposomes did not show a significant increase in tumor accumulation [14], and the modification of the antibody (anti-HER2) on long-circulating lipidic nanoparticles had no dramatic promotion in the accumulation at the tumor tissue [15].